Director, R&D New Modalities Portfolio
Waters Corporation
MILFORD, Massachusetts
Bala Addepalli, Bala_Addepalli@waters.com, is currently working as director of the Evaluations and Application Science Team under New Modalities (Cell and Gene Therapy product analysis) portfolio of Waters Corporation. His interests include development of simpler but efficient approaches for cell and gene therapy products such as messenger RNA (mRNA), lipid nanoparticle (LNP), and adeno-associated virus (AAV) analysis through liquid chromatography coupled with light scattering and mass spectrometry-based detection techniques. Prior to joining Waters, Addepalli developed novel enzymes and analytical methods for characterization of cellular RNA and modified oligonucleotides through mass spectrometry at University of Cincinnati. Before that he worked on RNA processing events including mRNA polyadenylation at University of Kentucky, and viral RNA characterization through mRNA translation for his graduate studies at Indian Agricultural Research Institute, New Delhi, India. Bala has authored over 60 publications in peer-reviewed scientific journals and has delivered oral presentations at scientific meetings.
Disclosure information not submitted.
Oligo mapping of Large RNA Therapeutics by Novel Enzyme Specificities
Monday, October 21, 2024
11:00 AM – 12:00 PM MT